FDA approves venetoclax for CLL or SLL, with or without 17 p deletion, after one prior therapy

On June 8, 2018, the Food and Drug Administration granted regular approval to venetoclax (VENCLEXTA, AbbVie Inc. and Genentech Inc.) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.



Leave a comment

Your email address will not be published.